Literature DB >> 11423259

Pathogenetic and histogenetic features of HIV-associated Hodgkin's disease.

R Dolcetti1, M Boiocchi, A Gloghini, A Carbone.   

Abstract

Compared with the cases in the general population, Hodgkin's disease (HD) arising in the HIV setting shows distinctive features in terms of epidemiology, aetiopathogenesis, histopathology and clinical behaviour. Although HD does not represent an AIDS-defining condition, recent evidence consistently indicates that HIV-infected individuals have a significantly increased risk of developing HD. HIV-related HD is characterised by the preponderance of aggressive histological subtypes, advanced stage at presentation, and highly malignant clinical course. Moreover, unlike HD in the general population, the large majority of HIV-related HD cases are pathogenetically linked to Epstein-Barr virus (EBV), with rates of EBV positivity ranging from 80 to 100%. Hodgkin and Reed-Sternberg cells of these cases invariably show a strong expression of the EBV-encoded latent membrane protein-1 (LMP-1), which functions as a constitutively activated tumour necrosis factor (TNF) receptor-like molecule. Usurpation of physiologically relevant pathways by LMP-1 may lead to the simultaneous or sequential activation of signalling pathways involved in the promotion of cell activation, growth, and survival, contributing thus to most of the features of HIV-related HD.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11423259     DOI: 10.1016/s0959-8049(01)00105-8

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  19 in total

Review 1.  EBV-associated lymphomas in adults.

Authors:  Mark Roschewski; Wyndham H Wilson
Journal:  Best Pract Res Clin Haematol       Date:  2012-02-05       Impact factor: 3.020

2.  Latent membrane protein 1 deletion mutants accumulate in reed-sternberg cells of human immunodeficiency virus-related Hodgkin's lymphoma.

Authors:  Massimo Guidoboni; Maurilio Ponzoni; Laura Caggiari; Antonia A Lettini; Luca Vago; Valli De Re; Annunziata Gloghini; Paola Zancai; Antonino Carbone; Mauro Boiocchi; Riccardo Dolcetti
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

3.  Non-AIDS-Defining Cancers and HIV Infection.

Authors:  Soon Thye Lim; Alexandra M Levine
Journal:  Curr Infect Dis Rep       Date:  2005-05       Impact factor: 3.725

4.  HIV positivity may not have a negative impact on survival in Epstein-Barr virus-positive Hodgkin lymphoma: A Japanese nationwide retrospective survey.

Authors:  Mihoko Yotsumoto; Yoshikazu Ito; Shotaro Hagiwara; Yasuhito Terui; Hirokazu Nagai; Yasunori Ota; Atsushi Ajisawa; Tomoko Uehira; Junko Tanuma; Kazuma Ohyashiki; Seiji Okada
Journal:  Oncol Lett       Date:  2018-07-11       Impact factor: 2.967

Review 5.  Non-AIDS-defining cancers and HIV infection.

Authors:  Soon Thye Lim; Alexandra M Levine
Journal:  Curr HIV/AIDS Rep       Date:  2005-08       Impact factor: 5.071

Review 6.  The biology of Hodgkin's lymphoma.

Authors:  Ralf Küppers
Journal:  Nat Rev Cancer       Date:  2008-12-11       Impact factor: 60.716

7.  Hodgkin's Disease in Patients with HIV Infection.

Authors:  Michele Spina; Antonino Carbone; Annunziata Gloghini; Diego Serraino; Massimiliano Berretta; Umberto Tirelli
Journal:  Adv Hematol       Date:  2010-09-23

Review 8.  Non-AIDS-defining malignancies in HIV-infected persons: etiologic puzzles, epidemiologic perils, prevention opportunities.

Authors:  Eric A Engels
Journal:  AIDS       Date:  2009-05-15       Impact factor: 4.177

9.  Sinonasal malignancies: a 10-year review in a tertiary health institution.

Authors:  Ayotunde J Fasunla; Akeem O Lasisi
Journal:  J Natl Med Assoc       Date:  2007-12       Impact factor: 1.798

10.  Longer duration of combination antiretroviral therapy reduces the risk of Hodgkin lymphoma: A cohort study of HIV-infected male veterans.

Authors:  M A Kowalkowski; M A Mims; R S Day; X L Du; W Chan; E Y Chiao
Journal:  Cancer Epidemiol       Date:  2014-06-16       Impact factor: 2.984

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.